For many in the device space, perseverance is an absolutely essential quality, the quality from which all else flows, and few people in this industry better exemplify the spirit and virtues of perseverance than Karen Talmadge, PhD, now executive vice president, co-founder and chief science officer at Kyphon, a spine company with a truly novel technology that today has a market cap of more than a billion dollars.
By David Cassak
It's often been said that success has many parents, but failure is an orphan. For a select few, success comes...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
